Valuation: Axsome Therapeutics, Inc.

Market Cap 10.16B 8.93B 8.45B 7.66B 14.39B 975B 14.47B 101B 39.06B 497B 38.13B 37.3B 1,599B P/E 2026 *
-71.9x
P/E 2027 * 43.7x
Enterprise Value 10.01B 8.8B 8.32B 7.55B 14.18B 961B 14.26B 99.66B 38.49B 490B 37.58B 36.76B 1,575B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 6.29x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day-2.72%
1 week-7.15%
Current month-5.00%
1 month-5.00%
3 months-21.79%
6 months+17.50%
Current year+3.26%
1 week 187.23
Extreme 187.23
204.7
1 month 187.23
Extreme 187.23
229.62
Current year 152.28
Extreme 152.28
260.19
1 year 117.3
Extreme 117.3
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Exercice

Chief Operating Officer

30,000 0.0573%
8/6/26 Exercice

Chief Executive Officer

13,980 0.0272%
7/1/26 Exercice

Chief Executive Officer

148,998 0.2895%
Change 5-day change 1-year change 3-year change Capi.($)
-2.87%-7.15%+60.33%+169.83% 10.16B
+1.93%+10.86%+699.01%+95.94% 78.76B
-0.75%-7.12%+33.15%-9.27% 75.12B
+0.21%+0.87%-8.39%-27.31% 61.14B
-1.27%-1.78%-7.86%+170.44% 46.07B
+2.49%-0.14%-8.95%+33.71% 47.57B
-0.74%+0.94%+64.21%-11.49% 33.79B
-1.05%-2.40%+47.67%+114.44% 25.3B
-0.26%-6.98%+2.46%+150.72% 21.34B
-0.34%-2.54%+56.34%+95.52% 15.36B
Average -0.24%+0.25%+93.80%+78.25% 41.46B
Weighted average by Cap. +0.20%+1.84%+147.49%+56.83%

Financials

2026 *2027 *
Net sales 964M 847M 801M 727M 1.36B 92.49B 1.37B 9.59B 3.71B 47.19B 3.62B 3.54B 152B 1.55B 1.36B 1.29B 1.17B 2.19B 149B 2.21B 15.41B 5.95B 75.81B 5.81B 5.68B 244B
Net income -142M -125M -118M -107M -201M -13.6B -202M -1.41B -545M -6.94B -532M -520M -22.3B 245M 215M 203M 185M 347M 23.48B 349M 2.44B 941M 11.98B 918M 898M 38.5B
Net Debt -148M -130M -123M -111M -209M -14.17B -210M -1.47B -568M -7.23B -554M -542M -23.23B -421M -370M -350M -318M -596M -40.41B -600M -4.19B -1.62B -20.62B -1.58B -1.55B -66.27B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
26-09-29 $188.23 -2.92% 39,821
26-09-28 $193.89 -0.62% 707,408
26-09-25 $195.09 -0.48% 838,181
26-09-24 $196.03 +1.33% 386,176
26-09-23 $193.45 -4.75% 912,995
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
193.89USD
Average target price
284.63USD
Spread / Average Target
+46.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock